Pituitary Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Pituitary cancer arising from the anterior pituitary gland accounts for approximately 15% of intracranial neoplasms and is typically benign. However, these tumors may metastasize and be referred to as pituitary carcinoma in rare cases. The underlying etiology of pituitary gland tumors is not fully understood but likely involves genetic abnormalities and alterations. Hereditary conditions such as multiple endocrine neoplasias (MEN)-1 syndrome are associated with an increased risk of pituitary tumors. The pathophysiology of pituitary cancer is believed to be genetically related, but specific gene mutations have yet to be fully identified. Pituitary tumors may be functional, secreting hormones and causing particular symptoms, or non-functional, without hormone production. The clinical presentation of pituitary tumors can include symptoms related to the mass effect on surrounding structures, such as the optic chiasm or cavernous sinus. Surgery is the primary treatment for pituitary carcinoma and is estimated to have been performed on 80.5% of patients, with some undergoing multiple surgeries. Radiotherapy is also used in treating pituitary carcinoma, with an estimated 42.9% of patients receiving at least two courses. Conformal radiotherapy, which aims to provide both antitumoral and antisecretory effects, can be considered, but data on its efficacy is limited. Chemotherapy, specifically with the oral alkylating agent temozolomide, is also used in treating pituitary carcinoma and has improved progression-free and overall survival rates. Antisecretory medications, such as dopamine agonists, steroidogenesis inhibitors, and somatostatin analogues, are also crucial in controlling pituitary hormone hypersecretion in patients with pituitary carcinoma.
- The incidence of Pituitary cancer ranges from 3.9 to 7.4 cases per 100,000 population in the USA.
Thelansis’s “Pituitary Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pituitary Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Pituitary Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Pituitary Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment